Bladder cancer thought leaders Drs. Sam Chang and Shilpa Gupta review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy.
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Division of Urologic Oncology, Vanderbilt Ingram Cancer Center, Nashville, TN
Director of the Genitourinary Medical Oncology
Cleveland Clinic
Co-Leader of the Genitourinary Oncology Program
Taussig Cancer Institute, Cleveland, OH
This CEC Oncology ONS Chapters Series is targeted to oncology nurses and advanced nurse practitioners serving as part of an interprofessional healthcare team providing care for pediatric and adult patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL).
This activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they’ve learned to real-world clinical scenarios.
This is a live webcast addressing emerging therapeutic options for gastric, GEJ, and EAC cancers. This activity will address PD-L1 expression and its impact on treatment selection and sequencing, as well as the role of interprofessional care in managing irAEs.
